CAJ | 학술논문

FLT3是一种受体型酪氨酸激酶，对造血细胞和淋巴细胞的增殖起关键作用。FLT3的异常激活与多种肿瘤特别是与急性髓性白血病的发生发展密切相关。以FLT3为靶点的小分子激酶抑制剂为多种肿瘤的治疗开辟了新途径，有许多FLT3抑制剂进入临床研究阶段，在靶向抗肿瘤领域有巨大的前景。本文主要对近年来的FLT3抑制剂的适应症及其研发状况进行综述。
FLT3시일충수체형락안산격매，대조혈세포화림파세포적증식기관건작용。FLT3적이상격활여다충종류특별시여급성수성백혈병적발생발전밀절상관。이FLT3위파점적소분자격매억제제위다충종류적치료개벽료신도경，유허다FLT3억제제진입림상연구계단，재파향항종류영역유거대적전경。본문주요대근년래적FLT3억제제적괄응증급기연발상황진행종술。
FLT3, a receptor tyrosine kinase, plays essential roles in hemopoiesis as well as the proliferation of lym-phocyte. The abnormal activated FLT3 was closely related to the development of many cancers, especially AML. As a potential target, FLT3 was intensively studied in current pharmaceutical development. Blocking FLT3 pathway provided a promising treatment for cancer. FLT3 inhibitors were registered for clinical trials, demonstrating great efficacy against can-cer. This review summarized the indication of FLT3 inhibitors and their research and development status in recent years.